GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (NAS:GLPG) » Definitions » Cyclically Adjusted PB Ratio

Galapagos NV (Galapagos NV) Cyclically Adjusted PB Ratio : 0.83 (As of May. 16, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Galapagos NV Cyclically Adjusted PB Ratio?

As of today (2024-05-16), Galapagos NV's current share price is $29.70. Galapagos NV's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $35.76. Galapagos NV's Cyclically Adjusted PB Ratio for today is 0.83.

The historical rank and industry rank for Galapagos NV's Cyclically Adjusted PB Ratio or its related term are showing as below:

GLPG' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.81   Med: 2.17   Max: 11.69
Current: 0.82

During the past years, Galapagos NV's highest Cyclically Adjusted PB Ratio was 11.69. The lowest was 0.81. And the median was 2.17.

GLPG's Cyclically Adjusted PB Ratio is ranked better than
68.58% of 646 companies
in the Biotechnology industry
Industry Median: 1.76 vs GLPG: 0.82

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Galapagos NV's adjusted book value per share data for the three months ended in Mar. 2024 was $47.752. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $35.76 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Galapagos NV Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Galapagos NV's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Cyclically Adjusted PB Ratio Chart

Galapagos NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 4.68 2.26 1.49 1.16

Galapagos NV Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.23 1.27 1.06 1.16 0.90

Competitive Comparison of Galapagos NV's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Galapagos NV's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galapagos NV's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galapagos NV's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Galapagos NV's Cyclically Adjusted PB Ratio falls into.



Galapagos NV Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Galapagos NV's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=29.70/35.76
=0.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galapagos NV's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Galapagos NV's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=47.752/130.5518*130.5518
=47.752

Current CPI (Mar. 2024) = 130.5518.

Galapagos NV Quarterly Data

Book Value per Share CPI Adj_Book
201406 10.261 99.482 13.466
201409 0.000 99.195 0.000
201412 8.389 99.086 11.053
201503 0.000 99.423 0.000
201506 12.796 100.107 16.688
201509 12.048 100.245 15.690
201512 10.175 100.572 13.208
201603 17.700 101.653 22.732
201606 17.784 102.267 22.703
201609 17.198 102.118 21.987
201612 17.302 102.614 22.013
201703 17.298 103.972 21.720
201706 23.613 103.902 29.669
201709 0.000 104.170 0.000
201712 23.512 104.804 29.288
201803 21.644 105.419 26.804
201806 20.154 106.063 24.807
201809 25.534 106.618 31.266
201812 25.363 107.252 30.873
201903 24.326 107.876 29.439
201906 23.566 107.896 28.514
201909 45.068 107.470 54.747
201912 49.410 108.065 59.692
202003 48.414 108.550 58.227
202006 47.859 108.540 57.565
202009 48.889 108.441 58.857
202012 49.664 108.511 59.752
202103 49.091 109.522 58.517
202106 48.976 110.305 57.966
202109 46.990 111.543 54.998
202112 45.564 114.705 51.859
202203 44.399 118.620 48.865
202206 42.569 120.948 45.949
202209 40.460 124.120 42.557
202212 40.645 126.578 41.921
202303 41.668 126.528 42.993
202306 42.483 125.973 44.027
202309 42.457 127.083 43.616
202312 46.263 128.292 47.078
202403 47.752 130.552 47.752

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Galapagos NV  (NAS:GLPG) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Galapagos NV Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Galapagos NV's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Galapagos NV (Galapagos NV) Business Description

Industry
Address
Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800
Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.